Atrigel is a registered trademark of QLT USA, Inc.
Visudyne is a registered trademark of Novartis AG.
Eligard is a registered trademark of Sanofi-aventis.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."
Certain statements in this press release constitute "forward-looking
statements" of QLT within the meaning of the Private Securities Litigation
Reform Act of 1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Such statements include,
but are not limited to, the statements relating to our plans to dispose of
or monetize value in certain non-core assets, statements relating to our
proposed acquisition of ForSight Newco II, Inc., including our expectation
that the acquisition will be successfully completed, anticipated scope and
cost of development work, potential targets, potential future product
opportunities and growth and timing of closing, and statements containing
words such as "expects," "will," "could," "intends," "should," "may,"
"plans," "believes," "potential" and similar expressions that do not relate
to historical matters. These forward-looking statements are only
predictions which involve known and unknown risks, uncertainties and other
factors that may cause actual events or results to differ materially.
Factors that could cause actual events or results to differ materially
include, but are not limited to: the risk that the proposed acquisition
fails to close due to closing conditions not being satisfied or for any
other reason, uncertainties relating to development and commercialization
of products and technologies and associated cost
|SOURCE QLT Inc.|
Copyright©2007 PR Newswire.
All rights reserved